HeartFlow Stock

heartflow.comHealthcareFounded: 2007Funding to Date: $528.88MM

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for HeartFlow, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Dana G Mead, Jr
President & Chief Executive Officer
Campbell Rogers, MD, FACC
Executive VP & Chief Medical Officer
Charles A Taylor, PhD
Founder & Chief Technology Officer
Lance Scott
Chief Commercial Officer
Noemi C Espinosa, JD
General Counsel, Chief Ethics and Compliance Officer
Renata Naoumov
VP & Chief People Officer
Christopher K Zarins, MD
Founder & Senior VP of Medical Affairs
Heather A Brown, PhD
Senior VP, Market Access and Reimbursement
Windi Hary, RAC
Senior VP, Clinical, Quality and Regulatory
Austin Davis
VP, Chief Information Security Officer

Board Members

John H Stevens, MD
William C Weldon
Dana G Mead, Jr
Jeffrey C Lightcap
HealthCor Partners Management
Lonnie M Smith
Intuitive Surgical
Casey Tansey
USVP
Charles A Taylor, PhD

Other companies like HeartFlow in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$2.51B
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$885.01MM
Sector
Last Round Est. Valuation
$355.29MM
Sector
Last Round Est. Valuation
$8.18B
Sector
Last Round Est. Valuation
$1.61B
Sector
Last Round Est. Valuation
$263MM
Sector
Last Round Est. Valuation
$67.5MM

News

For 2019, we asked companies around the world one basic question: “Please indicate the key technology which you believe will have the most profound impact on the healthcare industry during 2019?” The results are not very surprising:
The $1.5 billion health-tech startup HeartFlow has a noninvasive test for heart disease based on machine learning analysis of CT scans. Two new studies are unlikely to win over its critics.
The valuation is based on a big idea: a noninvasive test that peers into a patient’s coronary arteries to see how blocked they are.